Publications in collaboration with researchers from Netherlands Cancer Institute (9)

2024

  1. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

    Annals of Oncology, Vol. 35, Núm. 1, pp. 66-76

2023

  1. Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases

    Melanoma research, Vol. 33, Núm. 2, pp. 155-158

2021

  1. ERANET JTC 2011: Submission and Activation of an International Academic Translational Project in Advanced Breast Cancer. Experience From the ET-FES Study

    Frontiers in Medicine, Vol. 8

  2. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. European Breast Cancer Conference 12, October 2-3, 2020: Interview with the Chairs

    Breast Care

2019

  1. Next Generation-Targeted Amplicon Sequencing (NG-TAS): An optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA

    Genome Medicine, Vol. 11, Núm. 1

  2. POSEIDON trial phase 1B results: Safety, efficacy and circulating tumor DNA response of the beta isoform-sparing PI3K inhibitor taselisib (GDC-0032) combined with tamoxifen in hormone receptor positive metastatic breast cancer patients

    Clinical Cancer Research, Vol. 25, Núm. 22, pp. 6598-6605

2018

  1. A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation

    EMBO Molecular Medicine, Vol. 10, Núm. 12

  2. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

    Annals of Oncology, Vol. 29, Núm. 5, pp. 1203-1210